5mg of Mounjaro: What's the Wegovy Equivalent, and What Does It Cost You?

You're mid-titration on Mounjaro and wondering whether Wegovy would cost less at this stage

Picture the scenario: you've been on tirzepatide for a couple of months, you're at 5mg, things are moving in the right direction, but you've seen Wegovy prices and you're doing rough maths in your head. The appeal is obvious. Wegovy's titration schedule runs from 0.25mg up to a 2.4mg maintenance dose (with 7.2mg now also approved by the MHRA for eligible adults), which means its dose numbers look much smaller than tirzepatide's. But those numbers aren't measuring the same thing. Tirzepatide is a dual GIP and GLP-1 receptor agonist; semaglutide (Wegovy) activates the GLP-1 pathway only, and if you're wondering how much semaglutide is in Mounjaro, the answer is none, because tirzepatide is an entirely different molecule. The mechanisms are different enough that clinical teams don't convert one to the other the way you might convert currencies. According to NICE's appraisal of tirzepatide (TA1026), the medicines were compared in indirect analyses, not by swapping dose for dose. The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, pitted tirzepatide against semaglutide 2.4mg and found tirzepatide produced greater average weight loss overall, but that trial compared people at their highest tolerated doses, not at equivalent milligram points. So 5mg Mounjaro doesn't map onto any single Wegovy dose. What you can compare meaningfully is what each month of treatment actually costs you, and if you want a clear side-by-side breakdown, our page on how much Wegovy costs compared to Mounjaro walks through the current figures once everything is counted.

What UK private treatment actually costs, and what 'headline price' sometimes leaves out

UK private pricing for weight-loss injections is charged per pen or per month, and it varies between providers and by dose. Since Eli Lilly raised the UK list price for Mounjaro from 1 September 2025 (reported figures suggest the highest-dose pen rose from around £122 to around £330) private prices for tirzepatide across the market have typically ranged roughly £149 to £375 a month depending on dose and provider. Wegovy pricing varies too, though it has generally sat lower at comparable stages of treatment. Those figures are worth knowing, but they're also just a starting point. Headline prices from some providers don't include the consultation fee, the prescription charge, or delivery, each of which can add materially to the monthly total. Aftercare, dose-review support, and what happens if your treatment needs adjusting mid-month are sometimes excluded altogether. If you're doing a genuine like-for-like comparison, a detailed look at Mounjaro vs Wegovy price in the UK shows that the full cost difference across a course of treatment is often narrower than the initial price gap suggests, once you add those extras back in. The price breakdown between the two medicines is worth reading before you make any switches.

Where nume sits, and why we're not trying to be the cheapest option

At nume, one price covers everything: the clinical consultation, the prescription, the medicine, and free next-working-day delivery tracked through DPD in plain unbranded packaging. There are no bolt-on fees for aftercare or dose reviews. We don't run discount codes or promotional pricing, these are prescription-only medicines, and structuring them around voucher offers isn't something a responsible clinical service does. We are, by design, not the cheapest name you'll find when you search. That's a deliberate position, not an oversight. What the price buys is a pharmacist-led service with its own GPhC-registered pharmacy (registration 9012878), medicines sourced through the licensed UK supply chain, and a real prescriber reading your consultation on the day you submit it. Current treatment prices are listed on our treatment page, where you can also start your free consultation. You can read more about our clinical team on the prescriber profile page.

Why 'cheapest' is the wrong test for a prescription medicine

The MHRA has documented the risks clearly. Fake weight-loss pens have been seized in large quantities across the UK, some containing substances that caused serious harm to people who bought them believing they were genuine. Sellers offering these medicines without a full clinical assessment (and sometimes at prices well below the private market rate) are a documented safety risk. If the price looks dramatically lower than the range described above, or if the seller is promoting a "deal" on a prescription-only medicine, those are the flags the MHRA specifically asks patients to watch for; you can report suspect sellers at the Yellow Card scheme. For a prescription medicine, the relevant question isn't which provider shows the smallest number. It's whether the supply chain is licensed, whether a qualified prescriber has actually assessed your case, and whether there's clinical support if something changes. The full picture on which medicine costs less over time is a more useful frame than a single per-pen figure. So is understanding how the two medicines actually differ before you decide. Both start with a free consultation, that's the right place to begin.